CHRS vs. MLECW
CHRS (Coherus BioSciences, Inc.) and MLECW (Moolec Science SA Warrant) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, CHRS returned -32.03%/yr vs -37.99%/yr for MLECW. Their -0.03 correlation means they have often moved in opposite directions in the past.
Performance
CHRS vs. MLECW - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CHRS achieves a -0.70% return, which is significantly lower than MLECW's 184.48% return.
CHRS
- 1D
- -4.08%
- 1M
- -2.76%
- 6M
- -34.72%
- YTD
- -0.70%
- 1Y
- 60.63%
- 3Y*
- -32.03%
- 5Y*
- -35.92%
- 10Y*
- -25.65%
- ALL TIME*
- -17.11%
MLECW
- 1D
- -4.62%
- 1M
- 0.61%
- 6M
- 89.66%
- YTD
- 184.48%
- 1Y
- -11.76%
- 3Y*
- -37.99%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -72.35%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $622.50K | $1.07M | $1.63M | |
| $1.13K | $640.73 | $1.66K |
CHRS vs. MLECW - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
CHRS Coherus BioSciences, Inc. | -0.70% | 2.90% | -58.56% | -57.95% |
MLECW Moolec Science SA Warrant | 184.48% | -77.17% | 15.45% | -98.65% |
Correlation
The correlation between CHRS and MLECW is -0.04, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | -0.04 |
Correlation (3Y) Balances recent behavior with more history. | -0.02 |
Correlation (All Time) Calculated using the full available price history since Jan 3, 2023 | -0.03 |
Fundamentals
CHRS:
$172.60M
MLECW:
$179.72K
CHRS:
$46.88M
MLECW:
$7.83M
CHRS:
$23.41M
MLECW:
-$639.50K
CHRS:
-$162.15M
MLECW:
-$5.21M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CHRS vs. MLECW — Risk / Return Rank
CHRS
MLECW
CHRS vs. MLECW - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Coherus BioSciences, Inc. (CHRS) and Moolec Science SA Warrant (MLECW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CHRS | MLECW | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.67 | ||
| Sortino ratioReturn per unit of downside risk | -0.93 | ||
| Omega ratioGain probability vs. loss probability | 1.17 | 1.29 | -0.13 |
| Calmar ratioReturn relative to maximum drawdown | 1.10 | -0.16 | +1.25 |
| Martin ratioReturn relative to average drawdown | 1.82 | -0.23 | +2.05 |
Loading charts...
Drawdowns
CHRS vs. MLECW - Drawdown Comparison
The maximum CHRS drawdown since its inception was -98.21%, roughly equal to the maximum MLECW drawdown of -99.71%. Use the drawdown chart below to compare losses from any high point for CHRS and MLECW.
Loading charts...
Drawdown Indicators
| CHRS | MLECW | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.21% | -99.71% | +1.50% |
Max Drawdown (1Y)Largest decline over 1 year | -45.82% | -75.87% | +30.05% |
Max Drawdown (3Y)Largest decline over 3 years | -87.71% | -94.51% | +6.80% |
Max Drawdown (5Y)Largest decline over 5 years | -96.47% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -97.88% | — | — |
Current DrawdownCurrent decline from peak | -96.24% | -98.99% | +2.75% |
Average DrawdownAverage peak-to-trough decline | -63.91% | -97.31% | +33.40% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.56% | 51.71% | -24.15% |
Volatility
CHRS vs. MLECW - Volatility Comparison
The current volatility for Coherus BioSciences, Inc. (CHRS) is 16.17%, while Moolec Science SA Warrant (MLECW) has a volatility of 42.17%. This indicates that CHRS experiences smaller price fluctuations and is considered to be less risky than MLECW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CHRS | MLECW | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.17% | 42.17% | -26.00% |
Volatility (6M)Calculated over the trailing 6-month period | 48.53% | 180.44% | -131.91% |
Volatility (1Y)Calculated over the trailing 1-year period | 79.77% | 285.65% | -205.88% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 84.99% | 302.96% | -217.97% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 74.25% | 302.96% | -228.71% |
Dividends
CHRS vs. MLECW - Dividend Comparison
Neither CHRS nor MLECW has paid dividends to shareholders.
Financials
CHRS vs. MLECW - Financials Comparison
This section allows you to compare key financial metrics between Coherus BioSciences, Inc. and Moolec Science SA Warrant. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CHRS and MLECW have a correlation of -0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MLECW has higher volatility (42.17%) compared to CHRS (16.17%). In terms of maximum drawdown, CHRS dropped -98.21% vs MLECW's -99.71%.
CHRS currently has the higher Sharpe Ratio (0.63 vs -0.04), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CHRS and MLECW
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer